ccRCC Clinical Trials

2 recruiting

ccRCC Trials at a Glance

7 actively recruiting trials for ccrcc are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 1 with 5 trials, with the heaviest enrollment activity in Lake Success, New York, and Grand Rapids. Lead sponsors running ccrcc studies include GI Innovation, Inc., ITM Oncologics GmbH, and Elephas.

Browse ccrcc trials by phase

Treatments under study

About ccRCC Clinical Trials

Looking for clinical trials for ccRCC? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new ccRCC trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about ccRCC clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1Phase 2

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

MelanomaAdvanced Solid TumorsClear-Cell Renal-Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals240 enrolled11 locationsNCT06413680
Recruiting
Phase 1Phase 2

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Advanced Clear Cell Renal Carcinoma (Ccrcc)Papillary Renal Cell Carcinoma (Prcc)
National Cancer Institute (NCI)100 enrolled1 locationNCT05665361
Recruiting
Phase 3

Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC

Renal Cell Carcinoma (RCC)Clear Cell Renal Cell Cancer (ccRCC)Renal Cell Carcinoma (Kidney Cancer)+3 more
Telix Pharmaceuticals (Innovations) Pty Limited40 enrolled5 locationsNCT07197580
Recruiting
Phase 1Phase 2

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

Cervical CancerUrothelial CarcinomaAdvanced Solid Tumor+3 more
GI Innovation, Inc.317 enrolled8 locationsNCT04977453
Recruiting
Phase 1

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

Renal Cell CarcinomaClear Cell Renal Cell CarcinomaKidney Cancers+6 more
Neomorph, Inc30 enrolled7 locationsNCT07300241
Recruiting

Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform

CancerBladder CancerKidney Cancer+3 more
Elephas416 enrolled12 locationsNCT05520099
Recruiting
Phase 1Phase 2

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)Clear Cell Renal Cell Cancer (ccRCC)+4 more
ITM Oncologics GmbH270 enrolled10 locationsNCT05706129